07:00 , May 2, 2016 |  BC Week In Review  |  Company News

Cao Pharmaceuticals, NanoMaterials deal

Cao granted NanoMaterials’ NMT Pharmaceuticals Pte. Ltd. subsidiary exclusive, worldwide rights to develop and commercialize cancer candidate CZ-48 . The analog of camptothecin, a topoisomerase ( TOP1 ) inhibitor, was co-developed by Cao and NMT...